Andrew T. Miller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrew T. Miller has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Albert Parker
The Genomics Institute of the Novartis Research Foundation (GNF), San Diego, California, United States of America
1 shared publication- Amanda L. Vegoe
Center for Immunology, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA
1 shared publication Ben G. Wen
The Genomics Institute of the Novartis Research Foundation (GNF), San Diego, California, United States of America
1 shared publicationCarol Dahlberg
The Genomics Institute of the Novartis Research Foundation (GNF), San Diego, California, United States of America
1 shared publicationChristian Schmedt
The Genomics Institute of the Novartis Research Foundation (GNF), San Diego, California, United States of America
1 shared publicationCynthia Cienfuegos
The Genomics Institute of the Novartis Research Foundation (GNF), San Diego, California, United States of America
1 shared publication
Latest Publications
- Open Access
- 29 June 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (6) , e0131071
Inhibition of the Inositol Kinase Itpkb Augments Calcium Signaling in Lymphocytes and Reveals a Novel Strategy to Treat Autoimmune Disease
Emerging approaches to treat immune disorders target positive regulatory kinases downstream of antigen receptors with small molecule inhibitors. Here we provide evidence for an alternative approach in which inhibition of the negative regulatory inositol kinase Itpkb in mature T lymphocytes results in enhanced intracellular calcium levels following antigen receptor activation leading to T cell death. Using Itpkb conditional knockout mice and LMW Itpkb inhibitors these studies reveal that Itpkb through its product IP4 inhibits the Orai1/Stim1 calcium channel on lymphocytes. Pharmacological inhibition or genetic deletion of Itpkb results in elevated intracellular Ca2+ and induction of FasL and Bim resulting in T cell apoptosis. Deletion of Itpkb or treatment with Itpkb inhibitors blocks T-cell dependent antibody responses in vivo and prevents T cell driven arthritis in rats. These data identify Itpkb as an essential mediator of T cell activation and suggest Itpkb inhibition as a novel approach to treat autoimmune disease.
- 29 June 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (6) , e0131071
Open AccessInhibition of the Inositol Kinase Itpkb Augments Calcium Signaling in Lymphocytes and Reveals a Novel Strategy to Treat Autoimmune Disease
Emerging approaches to treat immune disorders target positive regulatory kinases downstream of antigen receptors with small molecule inhibitors. Here we provide evidence for an alternative approach in which inhibition of the negative regulatory inositol kinase Itpkb in mature T lymphocytes results in enhanced intracellular calcium levels following antigen receptor activation leading to T cell death. Using Itpkb conditional knockout mice and LMW Itpkb inhibitors these studies reveal that Itpkb through its product IP4 inhibits the Orai1/Stim1 calcium channel on lymphocytes. Pharmacological inhibition or genetic deletion of Itpkb results in elevated intracellular Ca2+ and induction of FasL and Bim resulting in T cell apoptosis. Deletion of Itpkb or treatment with Itpkb inhibitors blocks T-cell dependent antibody responses in vivo and prevents T cell driven arthritis in rats. These data identify Itpkb as an essential mediator of T cell activation and suggest Itpkb inhibition as a novel approach to treat autoimmune disease.
- 30 March 2011
- Published by Elsevier in Immunology Letters
- Vol. 135 (1-2) , 74-77
Tonic BCR signaling represses receptor editing via Raf- and calcium-dependent signaling pathways
- 30 March 2011
- Published by Elsevier in Immunology Letters
- Vol. 135 (1-2) , 74-77
Tonic BCR signaling represses receptor editing via Raf- and calcium-dependent signaling pathways